reviewTop 1% cited
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
European Journal of Cancer · 2017 · Vol. 81 · pp. 116–129
Leisha A. Emens✉(Johns Hopkins University)Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Phillip K. Darcy(The University of Melbourne)Sandra Demaria(Cornell University)Alexander M.M. Eggermont(Institut Gustave Roussy)William L. Redmond(Providence Portland Medical Center)Barbara Seliger(Martin Luther University Halle-Wittenberg)Francesco M. Marincola✉(Sidra Medical and Research Center)
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune Cell Function and InteractionMedicineImmunotherapyCancerCancer immunotherapyOncologyImmune checkpointDiseaseNivolumabInternal medicineImmunology
MeSH terms
Antineoplastic AgentsCombined Modality TherapyHumansImmunotherapyNeoplasmsMolecular Targeted TherapyCTLA-4 AntigenProgrammed Cell Death 1 Receptor
Citations
555
FWCI
23.90
field-weighted impact
References
137
Percentile
100%
vs. same field & year
Citations per year
Cited by
Breast Cancer Immunotherapy: Facts and Hopes
Clinical Cancer Research · 2017 · 917 citations
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Cancers · 2019 · 563 citations
References
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Journal of Clinical Oncology · 1996 · 2,101 citations
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
The Journal of Pathology · 2013 · 1,337 citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
The Lancet Oncology · 2014 · 1,480 citations
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Immunity · 2014 · 2,009 citations
Oncology Meets Immunology: The Cancer-Immunity Cycle
Immunity · 2013 · 6,760 citations
Cancer immunoediting: from immunosurveillance to tumor escape
Nature Immunology · 2002 · 5,232 citations
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Nature Medicine · 2007 · 2,933 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.